Navigation Links
New therapy shows promise for fighting treatment-resistant cancer cells

NEW ORLEANS, La.A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting. The new system targets oxygen-deficient hypoxic cancer cells that have activated a gene known as HIF-1, which ensures the cells' survival and makes them unresponsive to most current treatments.

"These types of cancer cells pose a significant challenge in treating many patients," said June-key Chung, a professor of nuclear medicine at Seoul National University College of Medicine, Seoul, South Korea, and lead researcher of the study, Human NIS Gene Radiotherapy Targeting HIF-1 Activated Cancer Cells. "Our research shows that this system successfully targets these hard-to-treat cells in vitro. Eventually, it could offer a novel way to develop new therapies for drug- and radiation-resistant cancers."

Hypoxic cancer cells are found in solid tumors that develop in many different cancers, including cancers of the liver, breast, prostate and uterus. Solid tumors undergo a multitude of cytogenetic or genetic changes over many years, some of which may resist almost any standard therapy.

"It is well known that hypoxic cancer cells are resistant to chemotherapy and radiotherapy, therefore creating a real dilemma for cancer therapies," said Chung. "Now, we are hopeful that new therapeutic models targeting resistant cancers, which are currently under development in the laboratory, can be successfully used for treatment. The results of our research imply that this is a real possibility."

Hypoxic cancer cells do not develop adequate blood vessels to receive oxygen. Because cells need oxygen to survive, hypoxic cells instead activate the HIF-1 protein, which changes cells' metabolism and enables them to burn sugar for energy without oxygen. Traditional cancer therapies are ineffective against hypoxic cells that have activated HIF-1 because HIF-1 regulates several genes related to the resistance of conventional cancer therapy.

In their research, Chung and his team developed a therapeutic system that targets HIF-1 human liver cancer cells in the laboratory. A reporter gene was developed that would express human sodium iodide symporter (hNIS) in the cancer cells. This gene would simultaneously track the cancer cells and treat them by allowing them to absorb iodine and radioisotope more easily. To improve imaging of the cancer cells even further, researchers also engineered the reporter gene to turn fluorescent when it encountered HIF-1 liver cancer cells so they could be tracked with optical imaging techniques. The reporter gene was then injected into human liver cancer cells. The results indicated that the system not only killed hypoxic liver cancer cells, but also could eventually be useful for visualizing how HIF-1 activation occurs in these cells.


Contact: Amy Shaw
Society of Nuclear Medicine

Related medicine news :

1. Modulated radiotherapy can cut treatment time for cancer of the rectum without increasing toxicity
2. Estrogen therapy helps or hurts the brain depending on reproductive status
3. Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer
4. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
5. Latest research on allergies: Specific immunotherapy can help
6. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
7. Breakthrough Isolaz(TM) Acne Therapy Featured in U.S. News & World Report:
8. Solid tumor cells not killed by radiation and chemotherapy become stronger
9. Specialist nurses can play a key role in supporting patients having radiotherapy
10. Majority of U.S. House Supports Repeal of Medicare Therapy Caps
11. Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology: